Please login to the form below

Not currently logged in
Email:
Password:

Lynparza

This page shows the latest Lynparza news and features for those working in and with pharma, biotech and healthcare.

AZ and MSD surpass rivals with updated Lynparza data

AZ and MSD surpass rivals with updated Lynparza data

AZ and MSD surpass rivals with updated Lynparza data. Aims for first-line indication in the ovarian cancer setting. ... data from SOLO-1 reinforces Lynparza’s ability to provide meaningful disease control with a well-characterised safety and

Latest news

More from news
Approximately 22 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare

    for Lynparza, the first in class PARP inhibitor now approved in ovarian and breast cancers.

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    in the EGFR-TK gene and Lynparza, which is approved to treat ovarian cancer patients with the BRCA mutation. “ ... 2015. “ Lynparza is for a very specific population of platinum sensitive relapse patients,” explains Anson. “

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics